Perrigo gets FDA approval for testosterone gel with $705M market
Perrigo (Nasdaq: PRGO) has received approval from the U.S. Food and Drug Administration for its New Drug Application for "testosterone gel 1%," which is comparable to AbbVie’s AndroGel 1% brand.
AndroGel is prescribed for adult males who have low or no testosterone. AndroGel sales are estimated to be approximately $705 million annually by Symphony Health.
“This filing is another example of our investment in new products and continued focus on bringing extended topicals to market. As always, Perrigo is committed to making quality health care more affordable for our customers and consumers,” said Perrigo Chairman/CEO Joseph C. Papa.
Allegan-based Perrigo is a global manufacturer of generic OTC and prescription pharmaceuticals.